Viatris Inc.
VTRS
Rank in Stocks
#1095
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its... Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Share Price
$18.55
Last synced: 2026-10-16
Market Cap
$21.31B
Change (1 day)
1.81%
Change (1 year)
82.40%
Country
US
Trade Viatris Inc. (VTRS)
Category
Healthcare
Operating Margin for Viatris Inc. (VTRS)
Operating Margin as of October 2026 TTM: -0.59%
According to Viatris Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is -0.59%. At the end of 2023 the company had an Operating Margin of 4.97%.
Operating Margin history for Viatris Inc. from 2004 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -0.59% | -942.86% |
| 2024 | 0.07% | -98.59% |
| 2023 | 4.97% | -49.95% |
| 2022 | 9.93% | -5,326.32% |
| 2021 | -0.19% | -89.20% |
| 2020 | -1.76% | -128.30% |
| 2019 | 6.22% | -21.46% |
| 2018 | 7.92% | -34.38% |
| 2017 | 12.07% | 91.28% |
| 2016 | 6.31% | -59.26% |
| 2015 | 15.49% | -11.59% |
| 2014 | 17.52% | 6.63% |
| 2013 | 16.43% | 0.67% |
| 2012 | 16.32% | -0.49% |
| 2011 | 16.40% | 23.87% |
| 2010 | 13.24% | 28.79% |
| 2009 | 10.28% | 77.24% |
| 2008 | 5.80% | -54.69% |
| 2007 | 12.80% | -44.01% |
| 2006 | 22.86% | -5.18% |
| 2005 | 24.11% | -33.03% |
| 2004 | 36.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -138.86% |
IN
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.